Cite
Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
MLA
Merli, Marco, et al. “Pharmacokinetics of Dolutegravir and Rilpivirine in Combination with Simeprevir and Sofosbuvir in HIV/Hepatitis C Virus-Coinfected Patients with Liver Cirrhosis.” The Journal of Antimicrobial Chemotherapy, vol. 72, no. 3, Mar. 2017, pp. 812–15. EBSCOhost, https://doi.org/10.1093/jac/dkw492.
APA
Merli, M., Galli, L., Marinaro, L., Ariaudo, A., Messina, E., Uberti-Foppa, C., Castagna, A., D’Avolio, A., Lazzarin, A., Bonora, S., & Hasson, H. (2017). Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. The Journal of Antimicrobial Chemotherapy, 72(3), 812–815. https://doi.org/10.1093/jac/dkw492
Chicago
Merli, Marco, Laura Galli, Letizia Marinaro, Alessandra Ariaudo, Emanuela Messina, Caterina Uberti-Foppa, Antonella Castagna, et al. 2017. “Pharmacokinetics of Dolutegravir and Rilpivirine in Combination with Simeprevir and Sofosbuvir in HIV/Hepatitis C Virus-Coinfected Patients with Liver Cirrhosis.” The Journal of Antimicrobial Chemotherapy 72 (3): 812–15. doi:10.1093/jac/dkw492.